Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors.
about
Angiotensin Converting Enzyme and Angiotensin II Type 1 Receptor Polymorphisms in Patients with Coronary AneurysmsMast Cell: A Multi-Functional Master CellThe Abdominal Aortic Aneurysm and Intraluminal Thrombus: Current Concepts of Development and TreatmentThe efficacy of pharmacotherapy for decreasing the expansion rate of abdominal aortic aneurysms: a systematic review and meta-analysis.The role of the renin-angiotensin system in aortic aneurysmal diseases.Medical management of small abdominal aortic aneurysmsEffects of vascular photodynamic therapy in a newly adapted experimental rat aortic aneurysm modelEfficacy and mechanism of angiotensin II receptor blocker treatment in experimental abdominal aortic aneurysms.Experimental models of abdominal aortic aneurysmsACE inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysmProspects for the medical management of abdominal aortic aneurysms.Impaired glutathione redox system paradoxically suppresses angiotensin II-induced vascular remodeling.Heat shock protein 90 inhibition by 17-DMAG attenuates abdominal aortic aneurysm formation in miceStatin therapy reduces growth of abdominal aortic aneurysms.Clonal expansion of T cells in abdominal aortic aneurysm: a role for doxycycline as drug of choice?Pharmacological targets in the treatment of abdominal aortic aneurysms.Role of the renin-angiotensin system in the development of abdominal aortic aneurysms in animals and humans.Matrix biology of abdominal aortic aneurysms in diabetes: mechanisms underlying the negative association.Pharmacological treatment of abdominal aortic aneurysm.An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK).Pharmacological therapy for patients with abdominal aortic aneurysm.Targeting chronic inflammation in cerebral aneurysms: focusing on NF-kappaB as a putative target of medical therapy.Abdominal aortic aneurysm screening: 2006 recommendations.Current and future pharmacological treatment strategies with regard to aortic disease in Marfan syndrome.Involvement of the renin-angiotensin system in abdominal and thoracic aortic aneurysms.Role of the renin-angiotensin system on abdominal aortic aneurysms.Prevention of abdominal aortic aneurysms by simultaneous inhibition of NFkappaB and ets using chimeric decoy oligonucleotides in a rabbit model.Inhibition of ets, an essential transcription factor for angiogenesis, to prevent the development of abdominal aortic aneurysm in a rat model.An update on the etiology of abdominal aortic aneurysms: implications for future diagnostic testing.Abdominal aortic aneurysms targeted by functionalized polysaccharide microparticles: a new tool for SPECT imaging.Inhibition or deletion of angiotensin II type 1 receptor suppresses elastase-induced experimental abdominal aortic aneurysms.Recent advances in pharmacotherapy development for abdominal aortic aneurysm.Statin use and rupture of abdominal aortic aneurysm.Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation.Angiotensin-II induces phosphorylation of ERK1/2 and promotes aortic adventitial fibroblasts differentiating into myofibroblasts during aortic dissection formation.
P2860
Q24800120-2041A0AF-4497-42DA-9ACC-6711D901F20CQ26771463-04F18936-0490-48D2-90ED-5DDE8DB4DF4EQ26776131-37C38539-FC5E-4655-9FE9-137724014CACQ33325496-A8152B56-5468-46BB-97E2-BC676F37E1C4Q33757332-6CBF5F5F-E99F-4FAB-9733-27036AC01882Q34103746-B31AF96E-343E-44AB-8AE5-FD456CF55DE9Q34228052-AC11C502-E08C-4A5C-8833-6DAC081C3852Q34506416-1DE9F6F4-1A35-4AFC-A935-1239ACF37BE1Q34518262-4BE21C9F-4B60-49A6-9CAB-EE623AB2188CQ34634364-8059BF6F-4B64-45E4-9DED-E61192E5A1B2Q35150958-B730EE71-9523-47CF-AB6A-86318AE3DAD5Q35364697-FC1AD1F5-9B12-423F-90C0-E81FDCE0A6D2Q35437393-89D25FBD-8EC6-4B58-BB56-12D146A9822BQ35560673-069295A8-1652-4D4E-8B95-99B08639E8CDQ35723666-74C7BDF8-1811-4306-8FF4-2794094D06C5Q36539470-6AB21C7C-E65A-4DB2-A373-A44FE898ABE7Q36689680-80D9304A-C0D4-46E0-A27C-3C41CF538E1EQ36830867-88479AF7-D63D-4734-B78A-DA0EB92FF176Q37489199-6DD3C051-350C-4B2F-AD70-CD5D2C9D1C82Q37529894-9311F213-A4A8-4EF9-8B9F-3118A65BB075Q37578569-E9D81BD5-5114-4C32-B4EB-86A60A5136F6Q37686535-CA6BE264-E202-4494-AFC4-529862A72148Q37763164-15FB141A-6554-4F66-9587-5C012C793AEDQ37991383-7DE6D5CA-9CDC-4A3A-9DD3-7267CF6001FBQ38025669-0AB09DAE-FA89-40D1-B60C-49C6EEDF0C28Q38153772-D590C503-DCCD-44F7-9471-E8569702218BQ38317012-EC644BDC-41D3-4F07-9BBF-45A3E3C8771DQ38328659-6936F45B-211B-4D60-9E9D-8A7B829C17E7Q38592117-364C7B9D-44FE-48F8-8EC1-F7E146A3C20EQ38688674-B3632CF2-C8B2-4D41-825D-EABEE56466E5Q38824336-98AAB5B0-17C9-40FF-A7F9-195E2A010651Q42322515-0A25443E-AA45-4487-86AF-83163B8B5F83Q44975687-E848A965-C168-41BE-925F-43E8AE5936C9Q50081720-96FF7390-1C57-41A2-B5C2-62D990296E97Q54390028-95E80902-D4FF-42AD-8913-7FF2586E4ACF
P2860
Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Suppression of experimental ab ...... -converting enzyme inhibitors.
@en
Suppression of experimental ab ...... -converting enzyme inhibitors.
@nl
type
label
Suppression of experimental ab ...... -converting enzyme inhibitors.
@en
Suppression of experimental ab ...... -converting enzyme inhibitors.
@nl
prefLabel
Suppression of experimental ab ...... -converting enzyme inhibitors.
@en
Suppression of experimental ab ...... -converting enzyme inhibitors.
@nl
P2093
P356
P1476
Suppression of experimental ab ...... -converting enzyme inhibitors.
@en
P2093
P304
P356
10.1067/MVA.2001.112810
P577
2001-05-01T00:00:00Z